$1,318.00
Thyroid eye disease (TED), also called Graves’ ophthalmopathy or orbitopathy, is an autoimmune disorder that causes inflammation in the orbital and retroocular tissues. It generally occurs as a manifestation of Graves’ disease, a condition in which the immune system attacks the thyroid gland, commonly affecting the eyes and skin. Although TED is usually found in Graves’ hyperthyroidism patients, some patients may have autoimmune euthyroid or hypothyroid thyroiditis. TED is mostly a mild, non-progressive, and self-limiting disease; however, in rare cases it can progress to vision loss. The negative impact of TED on the social and psychological well-being of individuals is an established consequence of the disease.
This Market Spotlight report covers the Thyroid Eye Disease (TED) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Definition
7 Patient segmentation
9 Symptoms
9 Risk factors
10 Diagnosis
11 TREATMENT
11 Medical treatment
11 Orbital radiotherapy
11 Surgical treatment
13 EPIDEMIOLOGY
13 Thyroid eye disease occurrence in thyroid disorders
13 Incidence methodology
17 MARKETED DRUGS
19 PIPELINE DRUGS
23 RECENT EVENTS AND ANALYST OPINION
23 VRDN-001 for Thyroid Eye Disease (August 15, 2022)
25 KEY UPCOMING EVENTS
26 PROBABILITY OF SUCCESS
27 LICENSING AND ASSET ACQUISITION DEALS
27 Amgen To Enhance Rare Disease Franchise With $27.8bn Horizon Takeover
27 CSPC Obtains Greater China Rights To Harbour BioMed’s Batoclimab
28 REVENUE OPPORTUNITY
29 CLINICAL TRIAL LANDSCAPE
30 Sponsors by status
31 Sponsors by phase
32 Recent events
34 BIBLIOGRAPHY
35 APPENDIX
LIST OF FIGURES
16 Figure 1: Trends in incident cases of thyroid eye disease, 2021–30
19 Figure 2: Overview of pipeline drugs for TED in the US
19 Figure 3: Pipeline drugs for TED, by company
19 Figure 4: Pipeline drugs for TED, by drug type
20 Figure 5: Pipeline drugs for TED, by classification
25 Figure 6: Key upcoming events in thyroid eye disease
26 Figure 7: Probability of success in the ophthalmology-other pipeline
29 Figure 8: Clinical trials in thyroid eye disease
29 Figure 9: Top 10 drugs for clinical trials in thyroid eye disease
30 Figure 10: Top 10 companies for clinical trials in thyroid eye disease
30 Figure 11: Trial locations in thyroid eye disease
31 Figure 12: Thyroid eye disease trials status
32 Figure 13: Thyroid eye disease trials sponsors, by phase
LIST OF TABLES
13 Table 1: Prevalence of thyroid eye disease in Graves’ disease
14 Table 2: Incident cases of thyroid eye disease, 2021–30
18 Table 3: Marketed drugs for thyroid eye disease
21 Table 4: Pipeline drugs for TED in the US
23 Table 5: VRDN-001 for Thyroid Eye Disease (August 15, 2022)
28 Table 6: Historical global sales, by drug ($m), 2017–21
28 Table 7: Forecasted global sales, by drug ($m), 2023–27
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!